Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494311 · ClinicalTrials.gov registry record · Phase 4
Rapydan Topical Anaesthesia for Arterial Cannulation
A Phase 4 study, sponsored by Medical University of Vienna.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT01494311 is a Phase 4 study that has completed, run by Medical University of Vienna. The registered enrollment target is 90 participants.
The verdict
NCT01494311, a Phase 4 study, has completed, sponsored by Medical University of Vienna.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
Arterial catheterization is painful and is associated with patient stress and anxiety. Analgesia is usually provided by subcutaneous injection of local anesthetic. An alternative is topical anaesthesia, such as Rapydan which is a novel topical anesthetic patch containing 70 mg each of lidocaine and tetracaine. We therefore tested the hypothesis that Rapydan patch analgesia is non-inferior to subcutaneous local anesthetic.
Interventions
- DRUG Placebo Patch
- DRUG Lidocaine/tetracaine patch
- DRUG Subcutaneous injection of 0.5 ml Lidocain 1%
- DRUG Subcutaneous injection of saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01494311
The ClinicalTrials.gov registry entry for NCT01494311 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of Vienna, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Patch is the first listed.
NCT01494311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01494311 about?
NCT01494311 is a clinical study titled "Rapydan Topical Anaesthesia for Arterial Cannulation". Arterial catheterization is painful and is associated with patient stress and anxiety. Analgesia is usually provided by subcutaneous injection of local anesthetic. An alternative is topical anaesthesia, such as Rapydan which is a novel topical anesthetic patch containing 70 mg each of lidocaine and ...
What is the current status of trial NCT01494311?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2011-03. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01494311?
The interventions under investigation include: Placebo Patch (DRUG), Lidocaine/tetracaine patch (DRUG), Subcutaneous injection of 0.5 ml Lidocain 1% (DRUG), Subcutaneous injection of saline (DRUG).
Who is sponsoring clinical trial NCT01494311?
This trial is sponsored by Medical University of Vienna, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.